Assay for and Treatment of Autoimmune Disease

The invention is directed to prognosis, diagnosis and treatment of autoimmune diseases, including SLE (systemic lupus erythematosus), type-1 diabetes, experimental allergic encephalomyelitis (EAE) and other, which demonstrate uniquely the presence abnormal double-negative (CD4- and CD8-) T cells expressing large numbers of type 1 K+ ion channels. Such channel expression parallels the ability to induce autoimmunity and therefore the invention is directed to an assay for, and consequent method of treatment of, autoimmune diseases based upon the identification, characterization and measurement of relative numbers of type 1 K+ ion channels in abnormal double-negative (CD4- and CD8-) T cells linked to such diseases.

Patents:
US 5,397,702

Type of Offer: Licensing



« More Biotech Patents
« More Medical Patents

---